Eric Venker Sells 355,161 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Key Points

• Eric Venker sold a total of 355,161 shares of Roivant Sciences on October 7th, representing a 19.09% decrease in his holdings, worth approximately $5.73 million.
• Roivant Sciences' stock has shown fluctuations, recently trading down 0.6% to $16.03, with a market capitalization of $10.95 billion.
• Analysts have mixed ratings on Roivant Sciences, with an average target price of $19.94, and firms like Guggenheim and Goldman Sachs recently increasing their price targets to between $21 and $24.

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 355,161 shares of the firm's stock in a transaction dated Tuesday, October 7th. The shares were sold at an average price of $16.15, for a total value of $5,735,850.15. Following the completion of the transaction, the chief executive officer owned 1,504,959 shares of the company's stock, valued at $24,305,087.85. The trade was a 19.09% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Eric Venker also recently made the following trade(s):

• On Wednesday, October 8th, Eric Venker sold 138,602 shares of Roivant Sciences stock. The stock was sold at an average price of $16.20, for a total value of $2,245,352.40.
• On Monday, October 6th, Eric Venker sold 171,396 shares of Roivant Sciences stock. The stock was sold at an average price of $16.34, for a total value of $2,800,610.64.
• On Tuesday, September 23rd, Eric Venker sold 611,000 shares of Roivant Sciences stock. The stock was sold at an average price of $14.83, for a total value of $9,061,130.00.
• On Monday, September 22nd, Eric Venker sold 416,182 shares of Roivant Sciences stock. The stock was sold at an average price of $14.99, for a total value of $6,238,568.18.
• On Friday, September 19th, Eric Venker sold 683,818 shares of Roivant Sciences stock. The stock was sold at an average price of $14.95, for a total value of $10,223,079.10.
• On Wednesday, August 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.72, for a total value of $1,172,000.00.
• On Monday, July 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.52, for a total value of $1,152,000.00.

Roivant Sciences Trading Down 0.6%

ROIV stock traded down $0.09 during mid-day trading on Wednesday, hitting $16.03. 5,850,620 shares of the company were exchanged, compared to its average volume of 9,553,693. The business has a 50 day simple moving average of $13.26 and a 200-day simple moving average of $11.71. The stock has a market capitalization of $10.95 billion, a PE ratio of -22.90 and a beta of 1.20. Roivant Sciences Ltd. has a 1-year low of $8.73 and a 1-year high of $16.79.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ROIV. Guggenheim lifted their price target on shares of Roivant Sciences from $15.00 to $21.00 and gave the company a "buy" rating in a research report on Thursday, September 18th. Leerink Partners boosted their price objective on shares of Roivant Sciences from $18.00 to $22.00 and gave the company an "outperform" rating in a research report on Thursday, September 18th. The Goldman Sachs Group boosted their price objective on shares of Roivant Sciences from $20.00 to $24.00 and gave the company a "buy" rating in a research report on Thursday, September 18th. Citigroup began coverage on shares of Roivant Sciences in a research report on Tuesday, September 2nd. They set a "buy" rating and a $16.00 price objective for the company. Finally, HC Wainwright upped their price target on shares of Roivant Sciences from $18.00 to $20.00 and gave the stock a "buy" rating in a report on Thursday, September 18th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $19.94.

Institutional Trading of Roivant Sciences

A number of institutional investors have recently bought and sold shares of the company. CWM LLC boosted its position in Roivant Sciences by 44.6% during the second quarter. CWM LLC now owns 2,984 shares of the company's stock valued at $34,000 after acquiring an additional 920 shares during the last quarter. Parallel Advisors LLC boosted its position in Roivant Sciences by 80.5% during the first quarter. Parallel Advisors LLC now owns 2,485 shares of the company's stock valued at $25,000 after acquiring an additional 1,108 shares during the last quarter. M&T Bank Corp boosted its position in Roivant Sciences by 10.2% during the second quarter. M&T Bank Corp now owns 12,802 shares of the company's stock valued at $144,000 after acquiring an additional 1,181 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Roivant Sciences by 16.6% during the 3rd quarter. GAMMA Investing LLC now owns 9,302 shares of the company's stock worth $141,000 after purchasing an additional 1,324 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of Roivant Sciences by 9.1% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 17,110 shares of the company's stock worth $173,000 after purchasing an additional 1,434 shares in the last quarter. Institutional investors own 64.76% of the company's stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.